RCD advises Reig Jofre on its acquisition of Bioibérica’s joint health product line
The listed pharmaceutical company adds a business line worth EUR 26M. Bioibérica is a leading manufacturer of the pharmaceutical ingredient Heparin and is known worldwide for its research, manufacturing, and marketing of animal-derived active ingredients
Reig Jofre has closed its EUR 46M acquisition of Bioibérica’s portfolio of finished pharmaceutical and nutraceutical products for joint health. RCD’s Corporate and Commercial Department advised on this transaction, which marks Reig Jofre’s first steps in the field of joint health and pain. The company will manage a portfolio of prescription and consumer healthcare products which is set to generate sales of approximately EUR 26M.
The deal has also added a team of 51 people and led to an agreement whereby Bioibérica will continue manufacturing and supplying the active ingredients needed for the products acquired by Reig Jofre. Bioibérica is a leading manufacturer of the pharmaceutical ingredient Heparin and is known worldwide for its research, manufacturing, and marketing of animal-derived active ingredients.
This new portfolio will allow Reig Jofre to diversify its operations by adding a joint health and pain division, a sector which is expected to grow significantly given the prevalence of osteoarticular diseases. It is estimated that between 5 and 20% of people suffer from them and up to 80% of people over 65 in industrialized countries are affected by them. In this sense, the agreement will boost development of the health prevention and care market for joint pain and will supplement treatment for osteoarticular diseases.
RCD has a strong track record advising life science companies on M&A deals and other needs through its multidisciplinary practice areas.
